Karyopharm Therapeutics is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets in cancer. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. The company was founded in 2008 with a vision of pioneering a potentially new approach to treating patients with certain blood cancers. For more information, visit Karyopharm.com.
|Access Date||Quiz Result||Score||Actions|
Please log in first before proceeding to the Sessions page
Please make sure the password is typed in ALL CAPS and includes the exclamation point. Enter the email address that you used to register for the conference.